ClinicalTrials.gg
RecruitingNCT04198792Updated Jan 20, 2026

Predictors for Survival and Good Neurological Outcome in E-CPR and Non CPR Treated Patients

An observational study in Cardiac Arrest, Extracorporeal Membrane Oxygenation and Hypoxia-Ischemia, Brain, sponsored by Sahlgrenska University Hospital. Recruiting at 1 site in Sweden. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Sahlgrenska University Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2010; still recruiting 16 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Heart Arrest with a site in Sweden — 4 open to participants now, 8 under way, none of them phase 3. Heart Arrest · Sweden.

Planned enrollment
7th of 12
700 · median 850
Started
2010
with 2 others
Observational
12 of 27
2 open now
Registered
17th of 27
by date
Lead sponsor
2 of 27
Sahlgrenska University Hospital

Among the 27 studies in Heart Arrest with a site in Sweden, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2010, is one of 12 observational ones, and was the 17th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

4 of the 27 studies in Heart Arrest with a site in Sweden are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Heart Arrest with a site in Sweden, or all of them as a file.
02

Study summary

In ECPR, where CPR times often range from 30 to 120 minutes, only patients with good circulation during CPR survive, while non-survivors commonly suffer from anoxic brain injury. The selection process during CPR is challenging causing a general survival rate of just 2 out of 10, and the urgent need for better selection criteria has been emphasized. It it crucial to keep cardiac arrest times as short as possible, pre primed-ECMO can facilitate this.

The ECMO treatment and the long CPR times of ECPR can also affect the measurements of the neurologic prognostication guidelines after cardiac arrest, making its validity uncertain in this specific cohort. Further, the long-term neuropsychological follow-up is limited to a few patients, making it uncertain if ECPR gives the survivors good long-term life satisfaction or just a prolonged life.

Our overall aim is to optimize and improve the care pathway for ECPR patients by refining patient selection, assessing pre-primed ECMO, validating neurological prognostication guidelines, and understanding long-term outcomes and challenges faced by survivors.

Specific Aim 1: Evaluating predictors for good neurological outcomes in ECPR and to develop and validate (internally and externally) an evidence-based selection tool for ECPR.

Specific aim 2: To assess the sterility and function of pre-primed ECMO.

Specific aim 3: To evaluate the applicability of current guidelines for neurological prognostication after cardiac arrest in ECPR patients, and to assess the predictive value of individual and combined neurological tests in this specific patient population.

Specific aim 4: To determine the long-term neuropsychological outcomes, identify the problems survivors experience in daily life, and assess life satisfaction - by comprehensive follow-up visits with validated questionnaires and neuropsychology testing up to 12 years after the ECMO-treated cardiac arrest.

Read the detailed description

Specific aim 1: The aim is to develop an ECPR prognostication tool and validate its performance. In development, possible predictors for good neurological outcomes are prospectively gathered. The predictive ability of the predictors is tested in univariate and multivariable analysis, with the aim of improving patient selection for ECPR. Patients from the Gothenburg ECPR cohort are included in the development study. External validation with the ECMO patients from the Prague OHCA trial, following guidelines for validation studies, will follow, as well as external validation with further patients from Gothenburg.

Specific aim 2: Cardiohelp ECMO circuits are set up dry, followed by wet-priming and used in the ECMO treatments of the centre. The circuits are cultured at ECMO-initiation and the incidence of positive cultures is assessed. The effect of the pre-primed time on ECMO function is also assessed.

Specific aim 3: The predictive ability of the current guideline for neurological prognostication of comatose patients in the ICU after cardiac arrest, from the European Resuscitation Council, is assessed in the ECPR cohort of Gothenburg. The diagnostic performance of individual predictors as well as the total accuracy of the prediction will be assessed.

Specific aim 4: A Long-term (1-12 years) follow-up of the ECPR patients will be performed, to determine the long-term neuropsychological outcomes.

4 A: Life satisfaction after ECPR will be assessed along with anxiety, depression, fatigue, cognitive function, and physical activity. The impact of these factors on life satisfaction will also be evaluated. QUALY will be calculated.

4 B: Long-term neurocognitive function in ECPR patients will be assessed through comprehensive neuropsychological testing, using conventional CPR patients from the TTM2 trial as a control group.

The general ECMO population from 2004 of the center is included as a control group and positive cultures during their ECMO runs are documented.

03

Conditions studied

  • Cardiac Arrest
  • Extracorporeal Membrane Oxygenation
  • Hypoxia-Ischemia, Brain
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

ECPR Group: Patients who is put on ECMO during cardiac arrest. ECMO Group: Patients who is put on ECMO with some ongoing circulaiton

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ECMO-treated patients.

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • ECPR patients

    Patients that is put om ECMO during cardiac arrest

    Other: No intervention

  • ECMO patients, non-ECPR

    Patients that is put on ECMO due to circulatory failure but not cardiac arrest

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention, but ECPR patients will be compared to ECMO-patients that have not had cardiac arrest

06

What researchers measure

Primary outcomes

  1. Modified Rankin scale (MRs)

    Assessmenty of cognitive function. 0-6, where 0 is best.

    Time frame: 1 year

  2. Performance of ECMO oxygenator function

    Oxygenator resistance, and the needed FiO2 and sweep gas flow will be assessed

    Time frame: 0-60 days

  3. Positive cultures of pre-primed ECMO circuits

    ECMO circuits is pre-primed and cultures taken at the start of ECMO treatment

    Time frame: 0-90 days

  4. Predictive ability of ERC neuro prognostication guidelines on ECPR patients

    Diagnostic performance and ROC analysis of individual and total ERC predictors on outcome in ECPR

    Time frame: 1 year

  5. Life Satisfaction

    Visual Analog Scale 1-10. 10 is better.

    Time frame: 1-12 years

  6. Euro Qualy - 5 dimension (EQ-5D-5L) VAS

    Self-perceived health status. 0-100, where higher is better.

    Time frame: 3 months to 12 years

  7. Neurocognitive function

    Z-scores of verbal and visual function, episodic and visuospatial memory , processing speed and executive functions. 0 represents standardized population norm and ± 1 represent one standard deviation from that.

    Time frame: 3 months to 12 years after the ECPR-treatment

  8. Positive blood Cultures

    Infection rates in ECMO-patients

    Time frame: 1 month

Secondary outcomes

  1. MoCA

    Assess cognitive function, higher is better. 0-30 where higher is better

    Time frame: 3 months to 12 years after the ECPR treatment

  2. Hospital Anxiety and Depression Scale (HADS)

    Two sub scales 0-21 which assess anxiety and depression, higer is worse

    Time frame: 3 months to 12 years

  3. Mental Fatigue Scale

    Assess fatigue 0-42 points. Higher is worse

    Time frame: 3 months to 12 years

  4. modified Rankin Scale

    physical function from 0-6 where 0 is best

    Time frame: 3 months to 12 years

  5. Actual physical activity

    Days per seven days with more than 30 minutes of physical activity

    Time frame: 3 months to 12 years

Other outcomes

  1. Cost

    The in hospital cost of the treatment for the patients, in Swedish kronor.

    Time frame: 3 month

  2. Short Form -36 (SF-36)

    Quality of life. 8 scaled scores from 0-100, where 100 is best.

    Time frame: 1-7 years

  3. Trailmaking test

    Assessmenty of cognitive function. Shorter time is better.

    Time frame: 1-7 years

  4. New York heart association class (NYHA class)

    Assessment of physical function.1-4, where 1 is best

    Time frame: 1-7 years

  5. Euro-Qualy-5D-5L

    Quality of life assessment, higher is better. Swedish value set -0.33 - 1.00

    Time frame: 3 moths to 12 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bengtsson D, Jonsson B, Redfors B. Sterility and oxygenator function in pre-primed extracorporeal membrane oxygenation: A prospective clinical study. Resusc Plus. 2024 Jun 5;19:100680. doi: 10.1016/j.resplu.2024.100680. eCollection 2024 Sep. PubMed 38912528 ↗
  • Redfors B, Byttner A, Bengtsson D, Watson P, Lannemyr L, Lundgren P, Gabel J, Rawshani A, Henningsson A. The Pre-ECPR Score: Developing and Validating a Multivariable Prediction Model for Favorable Neurological Outcomes in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation. J Cardiothorac Vasc Anesth. 2024 Dec;38(12):3018-3028. doi: 10.1053/j.jvca.2024.09.009. Epub 2024 Sep 17. PubMed 39395854 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2010 (actual). Primary completion is estimated for Jan 2030, 240 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 240 months is above that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Dec 13, 2019
StartActual
Jan 1, 2010
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2030
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04198792
Responsible party
Bengt Redfors (MD, PhD, Associate Professor, Sahlgrenska University Hospital) — Principal investigator
First posted
Dec 13, 2019
Start date
Jan 1, 2010
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Jan 20, 2026

Study contacts

Bengt Redfors, MD, PhD
Contact
bengt.redfors@vgregion.se
+46768445402
Anna Henningsson, MD
Contact
anna.henningsson@vgregion.se
+46700922555
Bengt Redfors, MD, PhD
principal investigator · The Sahlgrenska Academy ar Sahlgrenska University Hospital, Gorhenburg, Sweden

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion